Xenetic Biosciences updates investor presentation on Santersus share exchange, outlines pro forma valuation and 2027–2029 milestones
Menos de 1 minuto de leitura
Xenetic Biosciences released an updated investor presentation on its proposed share exchange with Santersus, outlining an illustrative ~85%/15% pro‑forma ownership split, estimated $141M valuation for Santersus and key clinical and regulatory milestones through 2029.
Key Highlights:
- Filed Item 7.01: furnished investor presentation on pending share exchange with Santersus; proxy and S‑1 to be filed with the SEC.
- Transaction terms (illustrative): Santersus valuation ~$141M (~85% post‑close) and Xenetic valuation ~$21M (~15% pre‑merger), subject to exchange ratio and adjustments.
- Combined company expected to list on Nasdaq under ticker SNTS; Santersus to become wholly owned subsidiary and operating business.
- Target close: Q4 2026 (subject to stockholder approvals and customary conditions); timelines include pivotal starts, interim readouts and regulatory submissions 2027–2029.
- Pipeline and milestones: NucleoCapture pivotal sepsis study (up to 350 pts) with interim analysis Q4 2027 and EU launch potential Q2 2028; SLE, liver transplant and DNase/LBCL programs with multiple readouts and regulatory plans through 2029.
Original SEC Filing: Xenetic Biosciences, Inc. [ XBIO ] - 8-K - Sep. 23, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.